Lung Cancer Clinical Trials
To Participate in any of these clinical trials or for more information:
Call us at (808) 586-2979
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Study Number | Study Details |
|---|---|
ALLIANCE-A151216 Local Principal Investigator: | Official Title: ALCHEMIST - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial Enrollment Status: Open: TCCOH, HCC, Hawaii Oncology, KMCWC, Straub, Pali Momi, Kuakini, QMC Cancer Type: Lung Keywords: Adjuvant Subtype: Adjuvant ClinicalTrials.gov ID: NCT02194738 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A081801 Local Principal Investigator: | Official Title: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO Enrollment Status: Open: HCC, Straub, Pali Momi, QMC Cancer Type: Lung Keywords: Adjuvant Subtype: Adjuvant ClinicalTrials.gov ID: NCT04267848 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-LUNGMAP Local Principal Investigator: | Official Title: LUNGMAP: A Master Protocol to Evaluate Biomarker-driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) Enrollment Status: Open: HCC, TCCOH, KMCWC, Straub, Pali Momi, QMC Cancer Type: Lung Keywords: Advanced/ Recurrent Subtype: Advanced/Metastatic 2nd line ClinicalTrials.gov ID: NCT03851445 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S1900E Local Principal Investigator: | Official Title: A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY) Enrollment Status: Open: HCC, Straub, Pali Momi, QMC Cohort 1 closed to accrual as of 12/13/2023 Cohort 2 will be closed to accrual as of 08/15/2024, Cohort 3 open Cancer Type: Lung Keywords: Advanced/ Recurrent Subtype: Advanced/Metastatic 2nd line ClinicalTrials.gov ID: NCT04625647 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S1900G Local Principal Investigator: | Official Title: A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) Enrollment Status: Open: HCC, QMC Opt out: HPH Cancer Type: Lung Keywords: Advanced/ Recurrent Subtype: Advanced/Metastatic 2nd line ClinicalTrials.gov ID: NCT05642572 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S2302 Local Principal Investigator: | Official Title: Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer Enrollment Status: Open: HCC, QMC, Straub, Pali Momi Cancer Type: Lung Keywords: Recurrent Subtype: Advanced/Metastatic 2nd line ClinicalTrials.gov ID: NCT05633602 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
NRG-LU008 Local Principal Investigator: | Official Title: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer Enrollment Status: Open: HCC, QMC XRT: QMC Opt out: HPH Cancer Type: Lung Keywords: Advanced Subtype: Advanced/Metastatic 2nd line ClinicalTrials.gov ID: NCT05624996 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S1827 Local Principal Investigator: | Official Title: A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer Enrollment Status: Open: TCCOH, HCC, Kuakini, Straub, Pali Momi, QMC Cancer Type: Lung Keywords: Post-adjuvant Subtype: Small Cell ClinicalTrials.gov ID: NCT04155034 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
